Dr. Dunne shared his expertise on, the integration of ctDNA in treatment decisions for colon cancer patients. Then the conversation lead to the significance of next-generation sequencing (NGS) and biomarker testing, followed by insights into the Code Break 301 trial and its potential impact on standard care for chemorefractory colorectal cancer.
Main Channel: https://www.youtube.com/@UCjfxKlVho5xWH5ltufj4F4A
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice!